Diagnos Inc. has closed a non-brokered private placement, raising $100,000 through the issuance of 10 units, each consisting of a $10,000 unsecured convertible debenture and 10,000 stock warrants. The proceeds will go towards product development, commercialization of AI-based screening services, and general administrative expenses. The private placement was subscribed by one director of the corporation, deemed a “related party.” All securities issued are subject to a statutory hold period until January 6, 2026. The transaction is exempt from certain valuation and approval requirements under MI 61-101. The private placement is subject to final approvals, including from the TSX Venture Exchange.

Read more at GlobeNewswire: DIAGNOS Announces Closing of Private Placement